These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27870706)

  • 1. Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy.
    Urban RR; Smith A; Agnew K; Bonato V; Goff BA
    Int J Gynecol Cancer; 2017 Feb; 27(2):233-238. PubMed ID: 27870706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Urban RR; Pappas TC; Bullock RG; Munroe DG; Bonato V; Agnew K; Goff BA
    Gynecol Oncol; 2018 Aug; 150(2):318-323. PubMed ID: 29929922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
    Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.
    Coleman RL; Herzog TJ; Chan DW; Munroe DG; Pappas TC; Smith A; Zhang Z; Wolf J
    Am J Obstet Gynecol; 2016 Jul; 215(1):82.e1-82.e11. PubMed ID: 26970494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay.
    Goodrich ST; Bristow RE; Santoso JT; Miller RW; Smith A; Zhang Z; Ueland FR
    Am J Obstet Gynecol; 2014 Jul; 211(1):65.e1-65.e11. PubMed ID: 24530816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative assessment of ovarian tumors using a modified multivariate index assay.
    Abdurrahman HA; Jawad AK; Alalalf SK
    J Ovarian Res; 2018 May; 11(1):41. PubMed ID: 29843758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
    Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
    Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.
    Longoria TC; Ueland FR; Zhang Z; Chan DW; Smith A; Fung ET; Munroe DG; Bristow RE
    Am J Obstet Gynecol; 2014 Jan; 210(1):78.e1-9. PubMed ID: 24055582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay.
    Miller RW; Smith A; DeSimone CP; Seamon L; Goodrich S; Podzielinski I; Sokoll L; van Nagell JR; Zhang Z; Ueland FR
    Obstet Gynecol; 2011 Jun; 117(6):1298-1306. PubMed ID: 21555961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
    Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
    Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
    Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
    Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
    Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
    Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.